Pregnancy or breast feeding <br/ >Hepatic cirrhosis <br/ >Alanine aminotransferase or aspartate aminotransferase more than five times the upper limit of normal <br/ >Known severe renal impairment (estimated glomerular filtration rate <30 mL/min per 1·73 m2) or receipt of continuous renal replacement therapy, haemodialysis, or peritoneal dialysis <br/ >Enrolment into an investigational treatment study for COVID-19 in the 30 days before screening <br/ >Patients of child-bearing age (men and women) not agreeing to take effective contraceptive measures (including hormonal contraception, barrier methods, or abstinence) during the study period and for at least 7 days after the last study drug administration <br/ >Any known hypersensitivity to the study drugs <br/ >Any patient belonging to Severe class of COVID19 disease as per GOI guidelines (MoHFW)

Pregnancy or breast feeding <br/ >Hepatic cirrhosis <br/ >Alanine aminotransferase or aspartate aminotransferase more than five times the upper limit of normal <br/ >Known severe renal impairment (estimated glomerular filtration rate <30 mL/min per 1·73 m2) or receipt of continuous renal replacement therapy, haemodialysis, or peritoneal dialysis <br/ >Enrolment into an investigational treatment study for COVID-19 in the 30 days before screening <br/ >Patients of child-bearing age (men and women) not agreeing to take effective contraceptive measures (including hormonal contraception, barrier methods, or abstinence) during the study period and for at least 7 days after the last study drug administration <br/ >Any known hypersensitivity to the study drugs <br/ >Any patient belonging to Severe class of COVID19 disease as per GOI guidelines (MoHFW)

N/A

N/A

Pregnancy or breast feeding <br/ >Hepatic cirrhosis <br/ >Alanine aminotransferase or aspartate aminotransferase more than five times the upper limit of normal <br/ >Known severe renal impairment (estimated glomerular filtration rate <30 mL/min per 1·73 m2) or receipt of continuous renal replacement therapy, haemodialysis, or peritoneal dialysis <br/ >Enrolment into an investigational treatment study for COVID-19 in the 30 days before screening <br/ >Patients of child-bearing age (men and women) not agreeing to take effective contraceptive measures (including hormonal contraception, barrier methods, or abstinence) during the study period and for at least 7 days after the last study drug administration <br/ >Any known hypersensitivity to the study drugs <br/ >Any patient belonging to Severe class of COVID19 disease as per GOI guidelines (MoHFW)

Pregnancy or breast feeding <br/ >Hepatic cirrhosis <br/ >Alanine aminotransferase or aspartate aminotransferase more than five times the upper limit of normal <br/ >Known severe renal impairment (estimated glomerular filtration rate <30 mL/min per 1·73 m2) or receipt of continuous renal replacement therapy, haemodialysis, or peritoneal dialysis <br/ >Enrolment into an investigational treatment study for COVID-19 in the 30 days before screening <br/ >Patients of child-bearing age (men and women) not agreeing to take effective contraceptive measures (including hormonal contraception, barrier methods, or abstinence) during the study period and for at least 7 days after the last study drug administration <br/ >Any known hypersensitivity to the study drugs <br/ >Any patient belonging to Severe class of COVID19 disease as per GOI guidelines (MoHFW)